P
Pauline Brice
Researcher at University of Paris
Publications - 243
Citations - 14207
Pauline Brice is an academic researcher from University of Paris. The author has contributed to research in topics: Brentuximab vedotin & Follicular lymphoma. The author has an hindex of 56, co-authored 227 publications receiving 12729 citations.
Papers
More filters
Journal ArticleDOI
Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature.
Patricia Pautier,Alain Devidas,Alain Delmer,Hervé Dombret,Laurent Sutton,Jean Marc Zini,Gerard Nedelec,Thierry Jo Molina,Jean Pierre Marolleau,Pauline Brice +9 more
TL;DR: AILD T-NHL still has a poor prognosis compared to other NHL and the role of intensive therapy and IFN alpha still remains to be evaluated.
Journal ArticleDOI
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Anne-Ségolène Cottereau,Annibale Versari,Annika Loft,Olivier Casasnovas,Monica Bellei,Romain Ricci,Stéphane Bardet,Antonio Castagnoli,Pauline Brice,John M. M. Raemaekers,Bénédicte Deau,Catherine Fortpied,Tiana Raveloarivahy,Emelie van Zele,Loïc Chartier,Thierry Vander Borght,Massimo Federico,Martin Hutchings,Umberto Ricardi,Marc André,Michel Meignan +20 more
TL;DR: B baseline positron emission tomography/computed tomography improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well.
Journal ArticleDOI
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
Sophie Bernard,Lauriane Goldwirt,Sandy Amorim,Pauline Brice,Josette Brière,Eric de Kerviler,Samia Mourah,Samia Mourah,Hélène Sauvageon,Catherine Thieblemont +9 more
TL;DR: It is confirmed that ibrutinib crosses the blood-brain barrier with parallel pharmacokinetic analyses in plasma and cerebrospinal fluid using a validated LC-MS/MS method and responses were ongoing after 2 months to 1 year of follow-up.
Journal ArticleDOI
High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin’s Lymphoma Responding to Front-Line Therapy
Angelo Michele Carella,Monica Bellei,Pauline Brice,Christian Gisselbrecht,Giuseppe Visani,Philippe Colombat,Francesco Fabbiano,Amedea Donelli,Stefano Luminari,Pierre Feugier,Peter Browett,Hans Hagberg,Massimo Federico +12 more
TL;DR: Patients with advanced unfavorable HL achieving CR or PR after four courses of doxorubicin-containing regimens have a favorable outcome with conventional chemotherapy, and no benefit from an early intensification with HDT and ASCT was shown.
Journal ArticleDOI
Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial
Isabelle Demeestere,Pauline Brice,Fedro A. Peccatori,Alain Kentos,Isabelle Gaillard,Pierre Zachee,Rene-Olivier Casasnovas,Eric Van Den Neste,Julie Dechene,Vivianne De Maertelaer,Dominique Bron,Yvon Englert +11 more
TL;DR: Triptorelin was not associated with a significant decreased risk of POF in young patients treated for lymphoma but may provide protection of the ovarian reserve.